IDEXX Laboratories, Inc.

As of June 30, 2026, IDEXX Laboratories, Inc. carries a market capitalization of 718.86B, placing it among publicly traded companies globally. Its enterprise value stands at 734.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IDEXX Laboratories, Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, IDEXX Laboratories, Inc. has 78.87M shares outstanding.

As of June 30, 2026, IDEXX Laboratories, Inc. trades at a trailing price-to-earnings ratio of 36.46. The price-to-sales ratio is 9.13, and the price-to-book ratio stands at 25.51.

As of June 30, 2026, IDEXX Laboratories, Inc. trades at an EV/EBITDA multiple of 26.07 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 28.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. IDEXX Laboratories, Inc. trades at an EV/FCF ratio of 33.18, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 734.57B versus a market cap of 718.86B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, IDEXX Laboratories, Inc. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 67.97, indicating elevated leverage, while an interest coverage ratio of 42.68 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, IDEXX Laboratories, Inc. posted a return on equity (ROE) of 74.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 42.22 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 33.65, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 43.29, useful for judging operating efficiency across full business cycles. The company generates approximately 7.23M in revenue per employee across its workforce of 11,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.36 indicates how many times IDEXX Laboratories, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, IDEXX Laboratories, Inc. recorded 4.98B in income tax expense. That works out to an effective tax rate of 19.99, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 24.89B, leaving 19.91B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, IDEXX Laboratories, Inc.'s stock has declined approximately 9.33% over the past 52 weeks. The 50-day moving average sits at 9,741.48, while the 200-day moving average is 10,124.06.

Over the twelve months ended June 30, 2026, IDEXX Laboratories, Inc. generated 79.55B in revenue and converted that into 19.91B in net income, yielding earnings per share of 248.41. EBITDA reached 28.18B, while operating income came in at 25.48B.

As of June 30, 2026, IDEXX Laboratories, Inc. holds 3.44B in cash and equivalents against 19.15B in total debt, resulting in a net debt position of 13.49B. Total book value stands at 28.17B, with working capital of 3.88B providing operational flexibility.

IDEXX Laboratories, Inc. produced 23.96B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.35B in capital expenditures, free cash flow totaled 21.61B - equivalent to 271.36 per share.

Over the twelve months ended June 30, 2026, IDEXX Laboratories, Inc. posted a gross margin of 62.45, reflecting its pricing power and cost economics. The operating margin of 32.03 and net profit margin of 25.03 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.96, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to IDEXX Laboratories, Inc. shareholders.

IDEXX Laboratories, Inc.'s most recent stock split took place on June 16, 2015 with a 1:2 split ratio.

As of June 30, 2026, IDEXX Laboratories, Inc. has an Altman Z-Score of 20.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.